ArticleBMC cancer2021
Association of chemotherapy with survival in stage II colon cancer patients who received radical surgery: a retrospective cohort study.
Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Age-related differences in adjuvant chemotherapy use and outcomes in stage II colon cancer: a retrospective cohort study.BMC cancer · 2025Article
- The Use of Artificial Intelligence in Predicting Chemotherapy-Induced Toxicities in Metastatic Colorectal Cancer: A Data-Driven Approach for Personalized Oncology.Diagnostics (Basel, Switzerland) · 2024Article
- Article
- Relationships Among Physical Activity, Sleep, and Cancer-related Fatigue: Results From the International ColoCare Study.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2024Observational
- Endoscopic obstruction predominantly occurs in right-side colon cancer and endoscopic obstruction with tumor size ≤ 5 cm seems poor prognosis in colorectal cancer.Frontiers in oncology · 2024Article
- Construction and validation of a prognostic nomogram for predicting cancer-specific survival in patients with intermediate and advanced colon cancer after receiving surgery and chemotherapy.Journal of cancer research and clinical oncology · 2023Article
- The prognostic activity of acylglycerol kinase immunohistochemical expression in colon adenocarcinoma patients.Przeglad gastroenterologiczny · 2023Article
- Clinical characteristics and prostate-cancer-specific mortality of competitive risk nomogram in the second primary prostate cancer.Frontiers in oncology · 2023Article
- Colorectal cancer survival among Malaysia population: data from the Malaysian National Cancer Registry.Frontiers in oncology · 2023Article
- Development and validation of a prognostic nomogram for patients with stage II colon mucinous adenocarcinoma.International journal of colorectal disease · 2022Article
- Adjuvant chemotherapy improves survival in high-risk stage II colon cancer: a retrospective cohort study.Therapeutic advances in gastroenterology · 2022Article
- Co-delivery of sorafenib and metformin from amphiphilic polypeptide-based micelles for colon cancer treatment.Frontiers in medicine · 2022Article
- Gender-specific nomogram models to predict the prognosis of male and female lung adenocarcinoma patients: a population-based analysis.Annals of translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt remains controversial whether patients with Stage II colon cancer would benefit from chemotherapy after radical surgery. This study aims to assess the real effectiveness of chemotherapy in patients with stage II colon cancer undergoing radical surgery and to construct survival prediction models to predict the survival benefits of chemotherapy.
methodsData for stage II colon cancer patients with radical surgery were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (1:1) was performed according to receive or not receive chemotherapy. Competitive risk regression models were used to assess colon cancer cause-specific death (CSD) and non-colon cancer cause-specific death (NCSD). Survival prediction nomograms were constructed to predict overall survival (OS) and colon cancer cause-specific survival (CSS). The predictive abilities of the constructed models were evaluated by the concordance indexes (C-indexes) and calibration curves.
resultsA total of 25,110 patients were identified, 21.7% received chemotherapy, and 78.3% were without chemotherapy. A total of 10,916 patients were extracted after propensity score matching. The estimated 3-year overall survival rates of chemotherapy were 0.7% higher than non- chemotherapy. The estimated 5-year and 10-year overall survival rates of non-chemotherapy were 1.3 and 2.1% higher than chemotherapy, respectively. Survival prediction models showed good discrimination (the C-indexes between 0.582 and 0.757) and excellent calibration.
conclusionsChemotherapy improves the short-term (43 months) survival benefit of stage II colon cancer patients who received radical surgery. Survival prediction models can be used to predict OS and CSS of patients receiving chemotherapy as well as OS and CSS of patients not receiving chemotherapy and to make individualized treatment recommendations for stage II colon cancer patients who received radical surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.